A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma Grant uri icon

  •  
  • Overview
  •  
  • Affiliation
  •  
  • View All
  •  

date/time interval

  • October 1, 2023 - October 31, 2031

total award amount

  • CAD 189044